Ambrx Biopharma Gross Profit 2020-2022 | AMAM

Ambrx Biopharma gross profit from 2020 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Ambrx Biopharma Annual Gross Profit
(Millions of US $)
2021 $7
2020 $14
2019 $10
Ambrx Biopharma Quarterly Gross Profit
(Millions of US $)
2022-06-30
2021-12-31 $7
2021-06-30
2020-12-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.030B 10.25
GSK (GSK) United Kingdom $69.877B 8.76
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.099B 18.95
Ginkgo Bioworks Holdings (DNA) United States $3.589B 0.00
Myovant Sciences (MYOV) United Kingdom $2.590B 0.00
Arcus Biosciences (RCUS) United States $2.209B 33.16
Biohaven (BHVN) United States $1.050B 0.00
Emergent Biosolutions (EBS) United States $0.587B 4.62
Zymeworks (ZYME) Canada $0.486B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.260B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.074B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00